Structure-modifying agents for osteoarthritis: An update

Joint Bone Spine

Volumn 71, Issue 1, 2004, Pages 18-23

  Richette, Pascal ^a   Bardin, Thomas ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Chondrometry; Osteoarthritis; Structure modifying agents; Symptomatic slow acting drugs for osteoarthritis

Indexed keywords

ANALGESIC AGENT; CHONDROITIN SULFATE; CHONDROSULF; DIACETYLRHEIN; GLUCOSAMINE SULFATE; GLYCOSAMINOGLYCAN PEPTIDE; GLYCOSAMINOGLYCAN POLYSULFATE; HYALURONIC ACID; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIASCLEDINE; PLACEBO; TRANSFORMING GROWTH FACTOR BETA;

ANALGESIA; ARTHRALGIA; ARTHROSCOPY; CLINICAL TRIAL; COMPUTER ANALYSIS; DRUG MECHANISM; GENE EXPRESSION REGULATION; HIP OSTEOARTHRITIS; HIP RADIOGRAPHY; HUMAN; JOINT CAVITY; JOINT FUNCTION; JOINT INJURY; KNEE ARTHROSCOPY; KNEE OSTEOARTHRITIS; KNEE RADIOGRAPHY; REVIEW; TREATMENT OUTCOME;

EID: 0842267170     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1297-319X(03)00129-5     Document Type: Review

References (69)

1. Felson D.T., Lawrence R.C., Dieppe P.A., Hirsch R., Helmick C.G., Jordan J.M., et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern M. 133:2000;635-646.
2. Felson D.T., Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum. 41:1998;1343-1355.
3. Recommendations for the registration of drugs used in the treatment of osteoarthritis. Ann Rheum Dis. 55:1996;552-557.
4. Altman R., Brandt K., Hochberg M., Moskowitz R., Bellamy N., Bloch D.A., et al. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop. Osteoarthritis Cart. 4:1996;217-243.
5. Lequesne M., Cadet C. Y a-t'il des antiarthrosiques chondroprotecteurs? Preuves exigibles. Therapie. 53:1998;7-16.
6. Lequesne M., Brandt K., Bellamy N., Moskowitz R., Menkes C.J., Pelletier J.P., et al. Guidelines for testing slow acting drugs in osteoarthritis. J Rheumatol. 41:1994;65-71.
7. Vignon E., Conrozier T., Piperno M., Richard S., Carrillon Y., Fantino O. Radiographic assessment of hip and knee osteoarthritis. Recommendations: recommended guidelines. Osteoarthritis Cart. 7:1999;434-436.
8. Brandt K.D., Mazzuca S.A., Conrozier T., Dacre J.E., Peterfy C.G., Provvedini D., et al. Which is the best radiographic protocol for a clinical trial of a structure modifying drug in patients with knee osteoarthritis? J Rheumatol. 29:2002;1308-1320.
9. Ravaud P., Dougados M. Radiographic assessment in osteoarthritis. J Rheumatol. 24:1997;786-791.
10. Lequesne M. Chondrometry. Quantitative evaluation of joint space width and rate of joint space loss in osteoarthritis of the hip. Rev Rhum Engl. 62:1995;155-158.
11. Conrozier T., Vignon E. Quantitative radiography in osteoarthritis: computerized measurement of radiographic knee and hip joint space. Baillieres Clin Rheumatol. 10:1996;429-433.
12. Maillefert J.F., Sharp J.T., Aho L.S., Dougados M. Comparison of a computer based method and the classical manual method for radiographic joint space width assessment in hip osteoarthritis. J Rheumatol. 29:2002;2592-2596.
13. Auleley G.R., Duche A., Drape J.L., Dougados M., Ravaud P. Measurement of joint space width in hip osteoarthritis: influence of joint positioning and radiographic procedure. Rheumatology. 40:2001;414-419.
14. Mazzuca S.A., Brandt K.D., Katz B.P. Is conventional radiography suitable for evaluation of a disease-modifying drug in patients with knee osteoarthritis? Osteoarthritis Cart. 5:1997;217-226.
15. Ravaud P., Auleley G.R., Chastang C., et al. Knee joint space width measurement: an experimental study of the influence of radiographic procedure and joint positioning. Br J Rheumatol. 35:1996;761-766.
16. Ravaud P., Giraudeau B., Auleley G.R., Drape J.L., Rousselin B., Paolozzi L., et al. Variability in knee radiographing: implication for definition of radiological progression in medial knee osteoarthritis. Ann Rheum Dis. 57:1998;624-629.
17. Buckland-Wight C. Current status of imaging procedures in the diagnosis, prognosis and monitoring of osteoarthritis. Bailleres Clin Rheumatol. 11:1997;727-748.
18. Mazzuca S.A., Brandt K.D., Lane K.A., Katz B.P. Knee pain reduces joint space width in conventional standing anteroposterior radiographs of osteoarthritic knees. Arthritis Rheum. 46:2002;223-227.
19. Buckland-Wright J.C., Macfarlane D.G., Williams S.A., Ward R.J. Accuracy and precision of joint space width measurements in standard and macroradiographs of osteoarthritic knees. Ann Rheum Dis. 54:1995;872-880.
20. Piperno M., Hellio Le Graverand M.P., Conrozier T., Bochu M., Mathieu P., Vignon E. Quantitative evaluation of joint space width in femorotibial osteoarthritis: comparison of three radiographic views. Osteoarthritis Cart. 6:1998;252-259.
21. Buckland-Wright J.C., Wolfe F., Ward R.J., Flowers N., Hayne C. Substantial superiority of semiflexed (MTP) views in knee osteoarthritis: a comparative radiographic study, without fluoroscopy, of standing extended, semiflexed AP, and schuss views. J Rheumatol. 26:1999;2664-2674.
22. Mazzuca S.A., Brandt K.D., Buckwalter K.A., Lane K.A., Katz B.P. Field test of the reproducibility of the semiflexed metatarsophalangeal view in repeated radiographic examinations of subjects with osteoarthritis of the knee. Arthritis Rheum. 46:2002;109-113.
23. Wolfe F., Lane N.E., Buckland-Wright C. Radiographic methods in knee osteoarthritis: a further comparison of semiflexed (MTP), schuss-tunnel, and weight-bearing anteroposterior views for joint space narrowing and osteophytes. J Rheumatol. 29:2002;2597-2601.
24. Ayral X., Dougados M., Listrat V., Bonvarlet J.P., Simonnet J., Amor B. Arthroscopic evaluation of chondropathy in osteoarthritis of the knee. J Rheumatol. 23:1996;698-706.
25. Hochberg M.C., Dougados M. Pharmacological therapy of osteoarthritis. Best Pract Res Clin Rheumatol. 15:2001;583-593.
26. Hauselmann H.J. Nutripharmaceuticals for osteoarthritis. Best Pract Res Clin Rheumatol. 5:2001;595-607.
27. Ayral X. Injections in the treatment of osteoarthritis. Best Pract Res Clin Rheumatol. 15:2001;609-626.
28. Bassleer C.T., Rovati L., Franchimont P. Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. Osteoarthritis Cart. 6:1998;427-434.
29. Bassleer C.T., Combal J.P., Bougaret S., Malaise M. Effects of chondroitin sulfate and interleukin-1 beta on human articular chondrocytes cultivated in clusters. Osteoarthritis Cart. 6:1998;196-204.
30. Kawasaki K., Ochi M., Uchio Y., Adachi N., Matsusaki M.J. Hyaluronic acid enhances proliferation and chondroitin sulfate synthesis in cultured chondrocytes embedded in collagen gels. Cell Physiol. 179:1999;142-148.
31. Yaron M., Shirazi I., Yaron. Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures. Osteoarthritis Cart. 7:1999;272-280.
32. Boumediene K., Felisaz N., Bogdanowicz P., Galera P., Guillou G.B., Pujol J.P. Avocado/soya unsaponifiables enhance the expression of transforming growth factor beta1 and beta2 in cultured articular chondrocytes. Arthritis Rheum. 42:1999;148-156.
33. Felisaz N., Boumediene K., Ghayor C., Herrouin J.F., Bogdanowicz P., Galerra P., et al. Stimulating effect of diacerein on TGF-beta1 and beta2 expression in articular chondrocytes cultured with and without interleukin-1. Osteoarthritis Cart. 7:1999;255-264.
34. Sandy J.D., Gamett D., Thompson V., Verscharen C. Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem J. 335:1998;59-66.
35. Brandt K.D., Smith G., Kang S.Y., Myers S., O'Connor B. Effects of diacerhein in an accelerated canine model of osteoarthritis. Osteoarthritis Cart. 5:1997;438-449.
36. Uebelhart D., Thonar E.J., Zhang J., Williams J.M. Protective effect of exogenous chondroitin 4,6-sulfate in the acute degradation of articular cartilage in the rabbit. Osteoarthritis Cart. 6:1998;6-13.
37. Cake M.A., Read R.A., Guillou B., Ghosh P. Modification of articular cartilage and subchondral bone pathology in an ovine meniscectomy model of osteoarthritis by avocado and soya unsaponifiables (ASU). Osteoarthritis Cart. 8:2000;404-411.
38. Dean D.D., Muniz O.E., Rodriquez I., Carreno M.R., Morales S., Agundez A., et al. Amelioration of lapine osteoarthritis by treatment with glycosaminoglycan-peptide association complex (Rumalon). Arthritis Rheum. 34:1991;304-313.
39. Rejholec V. Clinical trials of anti-osteoarthritic agents. Scand J Rheumatol. 81:1990;28-31.
40. Pavelka K., Gatterova J., Gollerova V., Urbanova Z., Sedlackova M., Altman R.D. A 5-year randomized controlled, double-blind study of glycosaminoglycan polysulphuric acid complex (Rumalon) as a structure modifying therapy in osteoarthritis of the hip and knee. Osteoarthritis Cart. 8:2000;335-342.
41. Raatikainen T., Vaananen K., Tamelander G. Effect of glycosaminoglycan polysulfate on chondromalacia patellae. A placebo-controlled 1-year study. Acta Orthop Scand. 61:1990;443-448.
42. Lequesne M., Samson M., Maheu E. Que penser des chondroprotecteurs? de Seze S., Ryckewaert A., Kahn M.F., Kuntz D., Dryll A. L'actualité rhumatologique 1994. 1994;347-360 Expansion Scientifique Française, Paris.
43. Lequesne M., Maheu E., Cadet C., Dreiser R.L. Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Rheum. 47:2002;50-58.
44. Dougados M., Nguyen M., Berdah L., Mazieres B., Vignon E., Lequesne M. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Arthritis Rheum. 44:2001;2539-2547.
45. Reginster J.Y., Deroisy R., Rovati L.C., Lee R.L., Lejeune E., Bruyere O., et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 357:2001;251-256.
46. Pavelka K., Gatterova J., Olejarova M., Machacek S., Giacovelli G., Rovati L.C. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern M. 162:2002;2113-2123.
47. McAlindon. Glusamine for osteoarthritis: dawn of a new era? Lancet. 357:2001;247-248.
48. Uebelhart D., Thonar E.J., Delmas P.D., Chantraine A., Vignon E. Evaluation of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cart. 6:1998;39-46.
49. Mathieu P. Radiological progression of internal femoro-tibial osteoarthritis in gonarthrosis. Chondro-protective effect of chondroitin sulfates ACS4-ACS6. Presse M. 31:2002;1386-1390.
50. Listrat V., Ayral X., Patarnello F., Bonvarlet J.P., Simonnet J., Amor B., et al. Arthroscopic evaluation of potential structure modifying activity of hyaluronan (Hyalgan) in osteoarthritis of the knee. Osteoarthritis Cart. 5:1997;153-160.
51. Jubb R.W., Piva S., Beinat L., Dacre J., Gishen P. Structure modification in osteoarthritis with intra-articular sodium hyaluronate of mol. 500-730 KDA. EULAR. 2001;. [Abstract] congress. OP0008.
52. Bennett L.D., Buckland-Wright J.C. Meniscal and articular cartilage changes in knee osteoarthritis: a cross-sectional double-contrast macroradiographic study. Rheumatology. 41:2002;917-923.
53. Adams J.G., McAlindon T., Dimasi M., Carey J., Eustace S. Contribution of meniscal extrusion and cartilage loss to joint space narrowing in osteoarthritis. Clin Radiol. 54:1999;502-506.
54. Dougados M., Gueguen A., Nguyen M., et al. Requirement for total hip arthroplasty: an outcome measure of hip osteoarthritis. J Rheumatol. 26:1999;855-861.
55. Maillefert J.F., Gueguen A., Nguyen M., Berdah L., Lequesne M., Mazieres B., et al. A composite index for total hip arthroplasty in patients with hip osteoarthritis. J Rheumatol. 29:2002;347-352.
56. NIH consensus development panel on total hip replacement. JAMA. 273:1995;1950-1956.
57. Lequesne M. The algofunctional indices for hip and knee osteoarthritis. J Rheumatol. 24:1997;779-781.
58. Hawker G.A., Wright J.G., Coyte P.C., et al. Differences between men and women in the rate of use of hip and knee arthroplasty. N Engl J M. 342:2000;1016-1022.
59. Hadorn H.C., Holmes A.C. ucation and debate: the New Zealand priority criteria project, part I: overview. BMJ. 314:1997;131-134.
60. Poole A.R. Can serum biomarker assays measure the progression of cartilage degeneration in osteoarthritis? Arthritis Rheum. 46:2002;2549-2552.
61. Vignon E., Garnero P., Delmas P., Avouac B., Bettica P., Boers M., et al. Recommendations for the registration of drugs used in the treatment of osteoarthritis: an update on biochemical markers. Osteoarthritis Cart. 9:2001;289-293.
62. Chevalier X., Conrozier T., Gehrmann M., Claudepierre P., Mathieu P., Unger S., et al. Tissue inhibitor of metalloprotease-1 (TIMP-1) serum level may predict progression of hip osteoarthritis. Osteoarthritis Cart. 9:2001;300-307.
63. Garnero P., Rousseau J.C., Delmas P.D. Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum. 43:2000;953-968.
64. Garnero P., Ayral X., Rousseau J.C., Christgau S., Sandell L.J., Dougados M., et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum. 46:2002;2613-2624.
65. Sugiyama S., Itokazu M., Suzuki Y., Shimizu K. Procollagen II C propeptide level in the synovial fluid as a predictor of radiographic progression in early knee osteoarthritis. Ann Rheum Dis. 62:2003;27-32.
66. Kawahara Y., Uetani M., Nakahara N., Doiguchi Y., Nishiguchi M., Futagawa S., et al. Fast spin-echo MR of the articular cartilage in the osteoarthrotic knee. Correlation of MR and arthroscopic findings. Acta Radiol. 39:(2):1998;120-125.
67. Broderick L.S., Turner D.A., Renfrew D.L., Schnitzer T.J., Huff J.P., Harris C. Severity of articular cartilage abnormality in patients with osteoarthritis: evaluation with fast spin-echo MR vs. arthroscopy. Am J Roentgenol. 162:1994;99-103.
68. Biswal S., Hastie T., Andriacchi T.P., Bergman G.A., Dillingham M.F., Lang P. Risk factors for progressive cartilage loss in the knee: a longitudinal magnetic resonance imaging study in forty-three patients. Arthritis Rheum. 46:2002;2884-2892.
69. Gandy S.J., Dieppe P.A., Keen M.C., Maciewicz R.A., Watt I., Waterton J.C. No loss of cartilage volume over three years in patients with knee osteoarthritis as assessed by magnetic resonance imaging. Osteoarthritis Cart. 10:2002;929-937.